Home » Newsletters » BioWorld Science

BioWorld Science

April 30, 2020

View Archived Issues

Lung changes from Parkinson's disease drug candidates are reversible

Platelets play role in Tylenol toxicity

Hepatic glutaminase 1 targeting reduces steatosis and decreases oxidative stress in NASH models

Chimerix initiates phase II/III study of DSTAT in patients with severe COVID-19

Promising data from compassionate care program of CAP-1002 in critical COVID-19 patients

Phase I data for SNDX-6352 as monotherapy and in combination with durvalumab presented

SVC-112 inhibits tumor growth in HNSCC models

First-in-human data presented for MOv18

Massachusetts General Hospital and collaborators patent SREBF1 inhibitors

Glo Pharma synthesizes new nicotinic acetylcholine receptor antagonists

BAY-2416964: an orally available AhR antagonist for the immunotherapy of advanced solid tumors

New CDK2/cyclin E inhibitors identifies at Incyte

Galecto Biotech presents new galectin-3 inhibitors

Autifony Therapeutics identifies new K(V)3 potassium channel modulators

Reprogramming microglial functional state has therapeutic potential for AD

AZD-9833: an orally available SERD presented by AstraZeneca

Phase II data presented for genolimzumab in peripheral T-cell lymphoma, alveolar soft part sarcoma

First-in-human data presented for TruUCAR-based GC-027

European Commission approves Ruconest to treat HAE attacks in children

Topline data from phase III study of 5- and 10-day dosing regimens of remdesivir in severe COVID-19

Jazz ends enrollment early in phase III trial of defibrotide for prevention of VOD

FDA approves Zejula as first-line maintenance for ovarian cancer regardless of biomarker status